articleTop 1% cited
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
The Lancet Oncology · 2015 · Vol. 16(2) · pp. 141–151
James Chih‐Hsin Yang✉(National Taiwan University Hospital)Yi‐Long Wu(Guangdong General Hospital)Martin SchülerMartin Sebastian(Goethe University Frankfurt)Sanjay Popat(Royal Marsden Hospital)Nobuyuki Yamamoto(Wakayama Medical University)Caicun Zhou(Shanghai Pulmonary Hospital)Cheng-Ping Hu(Central South University)Kenneth J. O’Byrne(Queensland University of Technology)Jifeng Feng(Jiangsu Cancer Hospital)Shun Lü(Shanghai Chest Hospital)Yunchao Huang(Kunming Medical University)Sarayut Lucien Geater(Prince of Songkla University)Kye Young Lee(Konkuk University Medical Center)Chun-Ming Tsai(Taipei Veterans General Hospital)В. А. ГорбуноваVera Hirsh(McGill University)Jaafar Bennouna(Institut de Cancérologie de l'Ouest)С. В. Орлов(First Pavlov State Medical University of St. Petersburg)Tony Mok(Chinese University of Hong Kong)Michael Boyer(Royal Prince Alfred Hospital)Wu‐Chou Su(National Cheng Kung University Hospital)Ki Hyeong Lee(Konkuk University Medical Center)Terufumi Kato(Kanagawa Cardiovascular and Respiratory Center)Dan Massey(Boehringer Ingelheim (United Kingdom))Mehdi Shahidi(Boehringer Ingelheim (United Kingdom))Victoria Zazulina(Boehringer Ingelheim (United Kingdom))Lecia V. Sequist(Harvard University)
Lung Cancer Treatments and MutationsCholangiocarcinoma and Gallbladder Cancer StudiesPlant Disease Resistance and GeneticsMedicineAfatinibPemetrexedLung cancerInternal medicineAdenocarcinomaLungGemcitabineChemotherapyPopulation
MeSH terms
AdenocarcinomaPemetrexedAfatinibGemcitabineAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCisplatinDeoxycytidineFemaleFollow-Up StudiesGlutamatesGuanineHumans
Citations
1,573
FWCI
165.50
field-weighted impact
References
29
Percentile
100%
vs. same field & year
Citations per year
Cited by
Targeting RTK Signaling Pathways in Cancer
Cancers · 2015 · 375 citations
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2016 · 2,632 citations
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2018 · 2,268 citations
References
Epidermal growth factor receptor mutations in lung cancer
Nature reviews. Cancer · 2007 · 3,115 citations
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Journal of Clinical Oncology · 2013 · 3,181 citations
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
The Lancet Oncology · 2012 · 5,500 citations
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
The Lancet Oncology · 2009 · 4,101 citations
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
The Lancet Oncology · 2011 · 4,075 citations
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
New England Journal of Medicine · 2009 · 8,201 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.